Downloads

  1. Mapping Candel Therapeutics' Sprint To The BLA Finish Line 4/22/2026

    Leaders from the adenovirus/prodrug developer discuss the complex balancing act of preparing to scale up for commercial manufacturing without overextension.

  2. Expanding The IV → SC Framework: What Reformulation Really Means 4/22/2026

    IV → SC is a system design challenge. Success depends on aligning formulation, device, manufacturing, and clinical strategy early to avoid costly failures and redesigns.

  3. Advancing Cell Therapy With The CTS DynaCellect Magnetic Separation System 4/21/2026

    Closed, automated T cell isolation with greater than 85% efficiency and greater than 96% purity is now achievable in 70 to 100 minutes, with cGMP-ready scalability from research to clinical manufacturing.

  4. Cell Therapy: T Cell Isolation From Whole Blood 4/21/2026

    Whole blood offers a faster, lower-cost starting material for T cell isolation and CTS Detachable Dynabeads CD4/CD8 with the DynaCellect System make it a viable, cGMP-aligned option without preprocessing.

  5. Cell Therapy Selection Guide: Connected From Activation To Expansion 4/21/2026

    Active bead release gives manufacturers precise control over T cell isolation timing, phenotype preservation, and workflow efficiency, eliminating multi-day passive dissociation delays.

  6. Achieving High Cell Purity With The CTS DynaCellect Magnetic Separation System 4/21/2026

    Learn how closed-system automation, combined with expert technical guidance and protocol optimization, turned a persistent manufacturing bottleneck into a reliable, scalable process.

  7. Robust, High-Throughput Automated Solution For Water Endotoxin Testing 4/21/2026

    High-throughput water endotoxin testing doesn’t have to sacrifice consistency. Gain insight into how an automated workflow delivers reliable results, low variability, and strong control recovery.

  8. Integrated T Cell Activation: Soluble DynActivator CD3/CD28 Prototype 4/21/2026

    Bead-free T cell activation is now achievable with a soluble, GMP-compliant format that supports up to 1.5 billion cells per vial, decouples activation from isolation, and removes with a simple cell wash.

  9. Dynabeads CD3 Depletion Prototype Supporting Solutions From Development To Delivery 4/21/2026

    Residual CD3+ cells shouldn't be the bottleneck in your allogeneic therapy workflow. This prototype achieves <0.5% residual T cells at commercial-scale processing capacity.

  10. Unlocking The Next Wave Of Cancer Vaccines 4/21/2026

    Discover how advanced ionizable LNP formulations and scalable manufacturing strategies can accelerate the development and clinical translation of personalized cancer vaccines.